Video

ESC 23: SurHyb Trial: Hybrid Ablation in Persistent Atrial Fibrillation

Published: 26 Aug 2023

  • Views:

    Views Icon 276
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating
View Transcript Download Transcript

 

ESC 2023 — Dr Alan Bulava (Ceske Budejovice Hospital and University of South Bohemia, CZ) joins us in this succinct interview to discuss the findings from the SurHyb trial.

 

The SurHyb study was a prospective, open-label-multicentre randomized trial. The study aimed to evaluate CryoMaze surgery alone, as compared to CryoMaze followed by radiofrequency catheter ablation 3-months post-surgery. 

 

Findings suggest that the incidence of atrial fibrillation and atrial tachycardia was reduced by 62%. The absolute risk reduction was 30%.

 

Questions:

  1. What is the reasoning behind this study?
  2. What was the patient population and study design?
  3. What are the key findings?
  4. What are the potential benefits of CryoMaze and Ablation? 
  5. How should these findings impact clinical practice?
  6. What further study is still required?

 

Recorded on-site at ESC Congress 2023, Amsterdam. 

For more content from ESC Congress 2023 head to the Hot Line & Late-breaking Science Video Collection.

Editors: Mirjam Boros and Jordan Rance
Video Specialists: Dan Brent, Tom Green, Mike Knight, Oliver Miles

Transcript

"My name is Alan Bulava. I come from Czechia, from the Budejovice hospital. I am chief of the department of arrhythmology and cardiac pacing. So responsible for the whole programme of arrhythmology programme at our institution.

Reasoning Behind the Study

The rationale behind the study was that we wanted to fill a gap because we do not know what exactly the post-procedural treatment of patients should be undergoing concomitant AF Ablation after cardiac surgery. Because recent literature indicates that about a quarter of patients undergoing cardiac surgery suffer from atrial fibrillation. And of course, in absolute numbers, it's a huge number. And even if you consider patients with mitral valve disease, it's even more than 50% of such patients. And nowadays, according to STS guidelines endorsed in 2017, these patients should be Ablated. So cardiac surgeons should perform cryomaze procedure to improve the patient's outcome, especially during mitral valve surgery, which is class 1A indication. And even with aortic valve surgery or simple coronary artery bypass grafting is a class 1B indication. But of course, the main drawback is that we do not know in which percentage these patients relapse with atrial fibrillation, so they reappear with atrial fibrillation again. So, we wanted to fill this obvious knowledge gap and that's why we initiated this investigator-initiated or open-label? Open label randomised control trial.

Patient Population and Study Design

The patient population was consisting of patients with non-paroxysmal type of atrial fibrillation. So, either persistent atrial fibrillation or long-standing persistent atrial fibrillation undergoing cardiac surgery procedures. So, either coronary artery bypass grafting or end valve repair. We excluded patients with extremely dilated atria, and we also excluded patients who underwent previous RF Ablation procedure for atrial fibrillation.

Key Findings

So, the key findings were that we were able, using hybrid approach, so deferred AF Ablation, catheter Ablation after cardiac surgery, after cryomaze, we were able to reduce the incidence of atrial fibrillation atrial tachycardia by 62%. So, the relative reduction risk was 62%. The absolute risk reduction was 30%. So, from 70% recurrence rate down to 40% recurrence rate, which is really huge and significant impact, taking into account that the monitoring of these patients was really intense. All the patients had cardiac implantable monitors, so we knew about almost, I would say almost every single AF recurrence.

How These Findings Should Impact Practice

This was our second question because it's not only about the AF reduction. So, to really propose this treatment, we should have some clinical outcome proven as well. And our primary clinical endpoint was reduction of hospitalisation for AF or ATEC hospitalisation for heart failure, significant bleeding or cardioembolic events. And all this combined clinical endpoint was also significantly reduced by 54%.

Further Study Required

Yeah, I think this is the first randomised trial in this field, obviously, and probably it should be confirmed by other randomised trials of that kind, which would then push a little bit more on the clinical impact. But basically, the finding of our trial is that we should propose the patients undergoing concomitant surgery for atrial fibrillation to undergo another procedure consisting of catheter ablation procedure to improve the clinical outcome and to improve or to reduce the burden of atrial arrhythmias.”

Comments

You must be to comment. If you are not registered, you can register here.